Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in severe uncontrolled refractory asthma (DREAM)
NCT01000506Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Primary completion
- Mar 2012
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of mepolizumab in asthma (4 arms), sponsored by GSK. Primary endpoint: Number of Clinically Significant Exacerbations of Asthma Per Year at 52 weeks. Started Nov 2009; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01000506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000506.